Building on the past to define an efficient path to an HIV vaccine

about

Stochastic simulations suggest that HIV-1 survives close to its error threshold Design of an Escherichia coli expressed HIV-1 gp120 fragment immunogen that binds to b12 and induces broad and potent neutralizing antibodies.

P2860

Q28483749-43EE7E3D-3635-4C91-B745-6790F5C1CC4C Q36742228-350B1B75-90DD-4205-8725-90FA12A9F090

P2860

Building on the past to define an efficient path to an HIV vaccine

Item

http://www.wikidata.org/entity/Q56880573

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в липні 2011

@uk

name

Building on the past to define an efficient path to an HIV vaccine

@en

Building on the past to define an efficient path to an HIV vaccine

@nl

type

Item

label

Building on the past to define an efficient path to an HIV vaccine

@en

Building on the past to define an efficient path to an HIV vaccine

@nl

prefLabel

Building on the past to define an efficient path to an HIV vaccine

@en

Building on the past to define an efficient path to an HIV vaccine

@nl

P1476

Building on the past to define an efficient path to an HIV vaccine

@en

P2860

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques.

HIV-1 vaccine development after STEP.

Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys.

Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant

Rational antibody-based HIV-1 vaccine design: current approaches and future directions

Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine

Public health. A sound rationale needed for phase III HIV-1 vaccine trials.

P304

929-931

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1586/ERV.11.81

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Bette Korber

P577

2011-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21806390

http://www.w3.org/2001/XMLSchema#string

Building on the past to define an efficient path to an HIV vaccine

about

P2860

P2860

Building on the past to define an efficient path to an HIV vaccine

description

name

type

label

prefLabel

P1433

P1476

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2860

P304

P31

P356

P433

P478

P50

P577

P698